Evogene Ltd. — Form SCHEDULE 13D/A
Filed July 20, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
L.I.A. Pure Capital Ltd. purchased 202,000 American Depositary Shares (ADSs) of Evogene Ltd. across three tranches between July 10–17, 2026, at prices ranging from $0.499 to $0.635 per ADS, for aggregate consideration of approximately $104,500. Each ADS represents one ordinary share. No material ownership threshold or control change is disclosed in the filing excerpt.
Why this rating
Schedule 13D/A amendment reporting routine open-market accumulation by single investor; no control threshold, strategy change, or governance impact evident. Stock price fluctuation during purchase window suggests no major market event.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.